WaveMan · Form 4
Gadicke Ansbert insider trades
> Search tickers & screens ⌘K
LIVE

Gadicke Ansbert insider trades

Gadicke Ansbert has filed 21 Form 4s with the SEC that we hold, for Cullinan Therapeutics, Inc. (CGEM) (10% owner), ITOS (10% owner), Kalaris Therapeutics, Inc. (ALVR) (Director, 10% owner) and TCRR (Director, 10% owner), among 6 companies in all. Across all of them we count 1 purchase worth $20.0M and 58 sales worth $29.0M reported on Form 4. In the last 12 months: 1 purchase ($20.0M) and 0 sales ($0). The largest single trade was a purchase of 1,112,777 shares of Aktis Oncology, Inc. worth $20.0M, dated 2026-01-12. The first filing on our record is dated 2021-07-13 and the latest 2026-01-14.

Cullinan Therapeutics, Inc. (CGEM)

10% owner · 11 filings · 38 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-08-11S, sale reported on Form 42,510$72.9K2021-08-12
2021-08-11S, sale reported on Form 4347$10.1K2021-08-12
2021-08-23S, sale reported on Form 453,359$1.6M2021-08-25
2021-08-23S, sale reported on Form 47,376$214.7K2021-08-25
2021-08-24S, sale reported on Form 450,882$1.5M2021-08-25
2021-08-24S, sale reported on Form 47,025$207.1K2021-08-25
2021-08-25S, sale reported on Form 41,713$49.8K2021-08-25
2021-08-25S, sale reported on Form 4237$6.9K2021-08-25
2021-08-27S, sale reported on Form 41,846$53.7K2021-08-31
2021-08-27S, sale reported on Form 413,357$388.6K2021-08-31
2021-08-30S, sale reported on Form 44,285$125.6K2021-08-31
2021-08-30S, sale reported on Form 431,001$908.3K2021-08-31
2021-08-31S, sale reported on Form 41,553$46.8K2021-09-02
2021-08-31S, sale reported on Form 4215$6.5K2021-09-02
2021-08-31S, sale reported on Form 41,285$37.8K2021-09-02
2021-08-31S, sale reported on Form 4177$5.2K2021-09-02
2021-09-01S, sale reported on Form 45,714$168.4K2021-09-02
2021-09-01S, sale reported on Form 4790$23.3K2021-09-02
2021-09-02S, sale reported on Form 42,178$64.2K2021-09-02
2021-09-02S, sale reported on Form 415,757$464.2K2021-09-02
2021-09-03S, sale reported on Form 41,760$52.1K2021-09-08
2021-09-03S, sale reported on Form 412,731$376.8K2021-09-08
2021-09-07S, sale reported on Form 43,465$100.6K2021-09-08
2021-09-07S, sale reported on Form 425,067$727.9K2021-09-08
2021-09-08S, sale reported on Form 410,842$315.6K2021-09-08
2021-09-08S, sale reported on Form 41,499$43.6K2021-09-08
2021-09-09S, sale reported on Form 413,727$402.9K2021-09-13
2021-09-09S, sale reported on Form 41,898$55.7K2021-09-13
2021-09-10S, sale reported on Form 45,931$172.2K2021-09-13
2021-09-10S, sale reported on Form 4820$23.8K2021-09-13
2021-09-13S, sale reported on Form 43,595$104.6K2021-09-13
2021-09-13S, sale reported on Form 4497$14.5K2021-09-13
2021-09-14S, sale reported on Form 4982$28.6K2021-09-16
2021-09-14S, sale reported on Form 47,106$207.3K2021-09-16
2021-09-15S, sale reported on Form 46,425$187.4K2021-09-16
2021-09-15S, sale reported on Form 4888$25.9K2021-09-16
2021-09-16S, sale reported on Form 43,124$90.8K2021-09-20
2021-09-16S, sale reported on Form 4432$12.6K2021-09-20

ITOS

10% owner · 5 filings · 16 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-09-14S, sale reported on Form 430,018$825.5K2021-09-16
2021-09-14S, sale reported on Form 46,063$169.7K2021-09-16
2021-09-15S, sale reported on Form 41,659$46.7K2021-09-16
2021-09-15S, sale reported on Form 438,677$1.1M2021-09-16
2021-09-21S, sale reported on Form 432,858$902.6K2021-09-23
2021-09-22S, sale reported on Form 423,921$658.8K2021-09-23
2021-10-01S, sale reported on Form 411,471$309.7K2021-10-05
2021-10-04S, sale reported on Form 434,659$937.9K2021-10-05
2021-10-12S, sale reported on Form 414,260$386.3K2021-10-14
2021-10-13S, sale reported on Form 435,023$950.2K2021-10-14
2021-10-14S, sale reported on Form 445,719$1.2M2021-10-14
2022-01-04S, sale reported on Form 412,829$596.2K2022-01-06
2022-01-04S, sale reported on Form 411,318$512.9K2022-01-06
2022-01-04S, sale reported on Form 432,396$1.4M2022-01-06
2022-01-04S, sale reported on Form 4158,579$6.7M2022-01-06
2022-01-05S, sale reported on Form 430,347$1.3M2022-01-06

Kalaris Therapeutics, Inc. (ALVR)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

TCRR

Director, 10% owner · 2 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-05-22S, sale reported on Form 470,170$131.9K2023-05-24

Aktis Oncology, Inc. (AKTS)

10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-01-12P, purchase reported on Form 41,112,777$20.0M2026-01-14

RPTX

10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-09S, sale reported on Form 44,067$134.5K2021-07-13
2021-07-12S, sale reported on Form 457,301$1.9M2021-07-13
2021-07-12S, sale reported on Form 4711$24.2K2021-07-13
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1134655) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms